Main description:

In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.

Contents:

Overview: Therapeutic Biomarkers in Cancer. Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer. Role of Biomarkers in Clinical Development of New Cancer Therapies. HER2 as a Prognostic and Predictive Biomarker in Cancer. Hormone Receptors and Endocrine Therapy in Breast Cancer. Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer. Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia. Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy. PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment. Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity. UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity. The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer. MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients. BRCA mutation and PARP Inhibitors. EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer. BRAF-Targeted Therapy in Metastatic Melanoma.